skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Percutaneous Intraductal Radiofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life

Abstract

PurposeThe clinical efficacy of intraductal radiofrequency ablation (RFA) with Habib™ EndoHPB catheter, a newly developed intervention for malignant extrahepatic biliary obstruction, remains uncertain. The aim of this study was to investigate the clinical efficacy of intraductal RFA.MethodsData from 71 patients with extrahepatic distal cholangiocarcinoma were retrospectively analyzed. The study patients were divided into RFA and control groups. The RFA group had undergone percutaneous transhepatic intraductal RFA with a Habib™ EndoHPB catheter, followed by placement of covered or uncovered biliary self-expandable metallic stents (SEMs) whereas the control group had undergone percutaneous transhepatic covered or uncovered SEMs placement. Procedure-related complications, stent patency, patient survival, and postoperative serum bilirubin concentrations were compared between the two groups. The Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire was administered to evaluate functional status, improvement in clinical manifestations, and quality of life.ResultsThe RFA group had a longer median stent patency than the control group (p = 0.001 for uncovered SEMs placement). Higher functional well-being, hepatobiliary-specific cancer subscale, Trial Outcome Index, and total FACT-Hep scores were observed during post-procedure follow-up in the RFA group. However, median survival did not differ significantly between the two groups (p > 0.05).ConclusionsProlongation of stent patency and better functional status and quality of life, which are allmore » important clinical endpoints, were observed in patients treated with intraductal RFA. Prospective randomized controlled clinical trials are necessary to further investigate the clinical efficacy and long-term benefits of intraductal RFA.« less

Authors:
;  [1];  [2];  [3];  [1];  [3]
  1. The 309th Hospital of PLA, Hepatobiliary Surgery Department (China)
  2. The 307th Hospital of PLA, General Surgery Department (China)
  3. The 309th Hospital of PLA, Radiology Department (China)
Publication Date:
OSTI Identifier:
22645341
Resource Type:
Journal Article
Resource Relation:
Journal Name: Cardiovascular and Interventional Radiology; Journal Volume: 40; Journal Issue: 2; Other Information: Copyright (c) 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ABLATION; BILIRUBIN; CLINICAL TRIALS; COMPARATIVE EVALUATIONS; CONCENTRATION RATIO; NEOPLASMS; PATIENTS; RADIOWAVE RADIATION; SCANNING ELECTRON MICROSCOPY; THERAPY

Citation Formats

Wu, Tian-tian, E-mail: matthewwu1979@hotmail.com, Li, Wei-min, E-mail: weimin-li-surgery@126.com, Li, Hu-cheng, E-mail: hucheng-li-surgery@126.com, Ao, Guo-kun, E-mail: guokun-ao-radiology@126.com, Zheng, Fang, E-mail: fang-zheng-surgery@126.com, and Lin, Hu, E-mail: hu-lin-radiology@126.com. Percutaneous Intraductal Radiofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life. United States: N. p., 2017. Web. doi:10.1007/S00270-016-1483-2.
Wu, Tian-tian, E-mail: matthewwu1979@hotmail.com, Li, Wei-min, E-mail: weimin-li-surgery@126.com, Li, Hu-cheng, E-mail: hucheng-li-surgery@126.com, Ao, Guo-kun, E-mail: guokun-ao-radiology@126.com, Zheng, Fang, E-mail: fang-zheng-surgery@126.com, & Lin, Hu, E-mail: hu-lin-radiology@126.com. Percutaneous Intraductal Radiofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life. United States. doi:10.1007/S00270-016-1483-2.
Wu, Tian-tian, E-mail: matthewwu1979@hotmail.com, Li, Wei-min, E-mail: weimin-li-surgery@126.com, Li, Hu-cheng, E-mail: hucheng-li-surgery@126.com, Ao, Guo-kun, E-mail: guokun-ao-radiology@126.com, Zheng, Fang, E-mail: fang-zheng-surgery@126.com, and Lin, Hu, E-mail: hu-lin-radiology@126.com. Wed . "Percutaneous Intraductal Radiofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life". United States. doi:10.1007/S00270-016-1483-2.
@article{osti_22645341,
title = {Percutaneous Intraductal Radiofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life},
author = {Wu, Tian-tian, E-mail: matthewwu1979@hotmail.com and Li, Wei-min, E-mail: weimin-li-surgery@126.com and Li, Hu-cheng, E-mail: hucheng-li-surgery@126.com and Ao, Guo-kun, E-mail: guokun-ao-radiology@126.com and Zheng, Fang, E-mail: fang-zheng-surgery@126.com and Lin, Hu, E-mail: hu-lin-radiology@126.com},
abstractNote = {PurposeThe clinical efficacy of intraductal radiofrequency ablation (RFA) with Habib™ EndoHPB catheter, a newly developed intervention for malignant extrahepatic biliary obstruction, remains uncertain. The aim of this study was to investigate the clinical efficacy of intraductal RFA.MethodsData from 71 patients with extrahepatic distal cholangiocarcinoma were retrospectively analyzed. The study patients were divided into RFA and control groups. The RFA group had undergone percutaneous transhepatic intraductal RFA with a Habib™ EndoHPB catheter, followed by placement of covered or uncovered biliary self-expandable metallic stents (SEMs) whereas the control group had undergone percutaneous transhepatic covered or uncovered SEMs placement. Procedure-related complications, stent patency, patient survival, and postoperative serum bilirubin concentrations were compared between the two groups. The Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire was administered to evaluate functional status, improvement in clinical manifestations, and quality of life.ResultsThe RFA group had a longer median stent patency than the control group (p = 0.001 for uncovered SEMs placement). Higher functional well-being, hepatobiliary-specific cancer subscale, Trial Outcome Index, and total FACT-Hep scores were observed during post-procedure follow-up in the RFA group. However, median survival did not differ significantly between the two groups (p > 0.05).ConclusionsProlongation of stent patency and better functional status and quality of life, which are all important clinical endpoints, were observed in patients treated with intraductal RFA. Prospective randomized controlled clinical trials are necessary to further investigate the clinical efficacy and long-term benefits of intraductal RFA.},
doi = {10.1007/S00270-016-1483-2},
journal = {Cardiovascular and Interventional Radiology},
number = 2,
volume = 40,
place = {United States},
year = {Wed Feb 15 00:00:00 EST 2017},
month = {Wed Feb 15 00:00:00 EST 2017}
}